Desci Project Aubrai launches the base to deal with the ‘Valley of Death’ of Science Funding

Longevity Research intersects in crypto by Aubrai, a decentralized science (I go down) and the AI ​​agent launched this week to the base As part of the bio protocol.

Decentralized science, or desci, Uses Blockchain and Daos to directly fund experiments.

The Aubrai token, which launches the Launchpad of the Bio Protocol, makes agent holders permanent stakeholders, with permanent stakeholders of funding decisions and a share of revenues from commercial discovery

Built by the Vitadao and Bio Protocol along with the Aubrey de Gray’s Lev Foundation, aimed at Aubrai bridge the “Valley of Death,” where long-horizon discovered the stall while capital market retreats and labs depend on philanthropy.

de gray is a Biomedical Gerontologist Introduced in Pioneering Longevity Research by his strategies for engineered neglected Senescence (Sens) Outline and for advocating that aging can be treated as a curable condition.

“The consequences of traditional financing are a chronic funding gap, excessive philanthropy, and a ‘death valley’ between discovery and clinic,” De Gray told CoinDesk in an interview.

“That is why we champion alternative mechanisms-held, funds dedicated to longevity, and desci platforms-which can tolerate long-reaching, aligning incentives around social benefits, and the risk of crowds,” De Gray said.

Aubrai’s approach combines De Gray’s lab’s unprofessional data with Onchain incentives. By drawing on de Gray’s lab’s unfolished data, Aubrai gains access to exclusive views beyond public literature, giving the agent a first-mover advantage in developing a novel, commercial associated hypotheses in the science of longevity.

The agent experiments experimented with a graph of knowledge, form hypotheses, and route them to token-holding votes for funding.

“We are already seeing the agent forming intriguing new hypotheses and recommend the next steps,” De Gray said. “It is the integration of the AI ​​Intelligence agent and expert human intelligence with the potential to notice the breakthrough in combating the accumulation.”

When experiments are proven, discoveries are printed on IP-TaKens that may be licensed to pharmaceutical or biotech companies, with revenues that cycling back to researchers and contributing.

The system is already in use in De Gray’s stable mouse mouse (Rmr2) Studyone of the largest experiments in the mouse life to be tried. Aubrai has suggested the methods of tweak and that are dosing caveats that researchers have discovered only after weeks of review.

“Having the agent at our disposal is changing for our planning pipeline,” said De Gray, noting that RMR2 involves nearly a dozen overlap study. “It has identified the points of consideration that we have not yet encountered by literature, and it is active in suggesting ways to avoid important limits.”

For Paul Kohlhaas, the founder of the Bio Protocol, Aubrai represents a point of order how to organize and fund science.

“As writers have given the ability to monetize outside the legacy media, the bio’s infrastructure can be scientists in the next great creator’s economy,” he said.

Come down i will face the challenges

While projects such as the Aubrai and Bio Protocol show the potential of crypto capital beyond the Memecoins, tokenized intellectual possession is likely to attract regulatory analysis, and established pharmaceutical companies may hesitate to adopt the findings that are born from decentralized collaps.

However, for a field such as longevity, where breakthroughs often die in space between early results and human trials due to an disinterested capital market, Aubrai offers an alternative path.

If it succeeds, it can show the blockchain’s potential to do more to the pump in the next memecoin. It can provide infrastructure to accelerate research itself, pushing the field of longevity closer to therapies that expand the human health span.

It will also signal that decentralized science can work as a viable market alternative to funding structures that have long been forced to change biomedical change.